



HFS

**Illinois Department of
Healthcare and Family Services**

JB Pritzker, Governor
Elizabeth M. Whitehorn, Director

401 S. Clinton St., Chicago, Illinois 60607
Telephone: +1 312-793-4792, TTY: +1 800-526-5812

Drug Utilization Review Advisory Board Meeting Minutes

Date | Time: Thursday, January 30, 2025 | 8:30 a.m. to 10:30 a.m.

Location: This meeting was held virtually via WebEx Webinar

Audience: Drug Utilization Review Advisory Board

Council Members Present:

Chair (*)

Vice-Chair (**)

Aneet Ahluwalia, MD

Chad Kodiak, PharmD

Bedrija Nikocecic, PharmD, BCACP**

Christopher Schriever, PharmD, MS, AAHIVP

Priti Shah, PharmD

Radhika Sreedhar, MD, MS, FACP*

Erica Stevens, PharmD, BCGP

Stefanie Toomey, PharmD

Santina Wheat, MD, MPH, FAAFP, AAHIVS

Absences Recorded:

None

HFS and UIC Staff Present:

Claudia Colombo

Arvind Goyal

Melissa Davis

Jose Jimenez

Jennifer DeWitt

Mary Moody

Thomas Dorn

Christina Petrykiw

Brianna Hudak

Maurice Shaw

Heather Freeman

Michael Welton

- I. **Call to Order, Roll Call:** The meeting was conducted via WebEx webinar format in accordance with the Open Meetings Act.
 - A. Dr. Radhika Sreedhar called the meeting to order at 8:31 a.m.
- II. **Roll Call of Council Members:** Dr. Sreedhar facilitated roll call of Board members. Quorum was confirmed.

- III. **Conflict of Interest Declaration and Approval of Agenda:** No DUR Advisory Board members had conflicts of interest pertinent to the agenda. Dr. Sreedhar reminded the Board members to recuse themselves from the discussion if conflicts of interest are present and to provide an updated Conflict of Interest form if new conflicts arise.
 - A. The current meeting agenda with no changes or additions was moved for approval by Dr. Schriever and seconded by Dr. Stevens. The motion was passed.
- IV. **Review and Approval of Meeting Minutes:** The minutes from October 31, 2024 were moved for approval by Dr. Schriever and seconded by Dr. Stevens. The motion was passed.
- V. **Approval of Destruction of Recorded Meeting Records 18 months and older:** A motion to destroy recorded meeting records dating back to July 2023 was made by Dr. Nikocecic and seconded by Dr. Wheat. The motion was passed.
- VI. **Board Updates:**
 - A. Resignations: Dr. Ihab Aziz resigned from the Board on December 23, 2024 and was thanked for his service.
 - B. New Board members: Chad Kodiak, PharmD, Priti Shah, PharmD, and Stefanie Toomey, PharmD, welcomed to the Board.
 - C. Board OneNet 2025 annual training modules must be completed by December 31, 2025.
- VII. **Retrospective DUR:** Concomitant clonazepam-opioid provider outreach
 - A. Pharmacy and medical claims for Fee-for-Service (FFS) participants filling concomitant clonazepam with opioids from April 1, 2024, to June 30, 2024, who did not have a medical claim for seizure or panic disorder were reviewed to determine the presence of first-line anxiety therapy. Less than one-third were filling first-line therapy. Morphine milligram equivalent value for the opioids was 5-15.
 - B. Clonazepam diagnosis provided by the prescriber was presented. Patients will be enrolled in the pain management program as appropriate.
 - C. Discussion: Although the outreach was deemed worthwhile, low prescriber response rates stimulated discussion of potential hard edits, which may be a more time-efficient process.
 - D. Motion to get detailed information about possible edit exclusions from the vendor and to provide Academic Detailing to prescribers who have not responded to the concomitant opioid-clonazepam DUR outreach was made by Dr. Sreedhar and seconded by Dr. Nikocecic. The motion was passed.
 - E. Naloxone in participants filling concomitant opioids with clonazepam: Outreach by telephone and/or fax to prescribers of FFS participants filling concomitant therapy who did not have naloxone filled in the past 2 years addressed clinical recommendations for naloxone provision and Illinois Public Act 720 ILCS 570-322.
 - 1. Pre- and post-intervention naloxone utilization presented. Outcomes: naloxone was prescribed, will be discussed at the next participant visit, or will be provided by the clinic.
 - 2. Discussion: Low naloxone prescribing rates were concerning and not reflective of evidence-based practice or legislative mandates. Board members discussed potential hard edits to facilitate naloxone prescribing and community availability of naloxone without a prescription.
 - 3. Motion to have a look-back period of 3 years for naloxone fill when an opioid prescription is filled. If no naloxone filled, the pharmacy should dispense naloxone via standing order made by Dr. Sreedhar and seconded by Dr. Schriever. Dr. Kodiak abstained from the vote. The motion was passed.

- VIII. **Prospective DUR:** Rescue inhaler utilization in participants with asthma
- A. Single-inhaler Maintenance and Reliever Therapy (SMART) therapy guidelines reviewed.
 - B. Data for FFS pediatric and adult participants who received three or more short-acting beta agonist (SABA) inhalers over a 12-month period were presented.
 - C. Quantity limits for SABA inhalers and nebulizer solutions in select FFS Medicaid programs reviewed.
 - D. Discussion: Board recommended Academic Detailing educational outreach to providers regarding SMART therapy and updated asthma guidelines.
 1. No official motions made.
- IX. **Education**
- A. Vitamin D guidelines
 - B. Asthma Therapy: Quick Reference Guide
 - C. Motion made to add a link to the vitamin D Endocrine Society guidelines and post the Asthma Therapy: Quick Reference Guide on the HFS DUR Education website by Dr. Sreedhar and seconded by Dr. Schriever. The motion was passed.
- X. **Quarterly Reports**
- A. Top 10 spend FFS drugs (2024Q3)
 1. Ribociclib (Kisqali®) for breast cancer and paliperidone palmitate (Invega Sustenna, Trinza, Halfyera) an antipsychotic, were new to the top 10.
 2. Discussion: Motion to review utilization of different paliperidone formulations to see which dosage forms impact spend made by Dr. Sreedhar and seconded by Dr. Schriever. The motion was passed.
 - B. Top 10 script count prescription FFS only (2024Q3)
 1. No changes from the previous quarter.
 - C. Top 10 script count over the counter (OTC) only (2024Q3)
 1. No major changes from the previous quarter.
 2. Board requested a breakdown of participant types receiving ferrous sulfate tablets (i.e. CILA, SLF).
 3. Motion made to provide more context for how the data that drives the top 10 script counts and spend made by Dr. Sreedhar and seconded by Dr. Schriever. The motion was passed.
- XI. **Public Comments**
- A. Huzefa Master, Director of pharmacy for Meridian, commented that Meridian covers select OTC medications for Illinois Medicaid participants.
- XII. **Announcements, Updates**
- A. New/Old Business: No new or old business updates.
 - B. Board suggestions for DUR topics.
 1. New diabetes guidelines updating what medications should be used first line.
 2. GLP-1 RA inhibitors for obstructive sleep apnea.
 - C. Announcements
 1. Provider Notice, 11/12/2024: Confirmation of coverage for hormonal therapy to treat menopause induced by a hysterectomy.
 2. Provider Notice, 11/27/2024: Notification of updated continuous glucose monitor (CGM) prior authorization criteria.

3. American Drug Utilization Review Society (ADURS) 2025 annual symposium will be held from February 20-22 in San Diego, CA. Dr. Petrykiw and Dr. Colombo will be attending.
 4. Dr. Chris Schriever was appointed to serve as a member of ASHP Section of Pharmacy Educators Advisory Group on development of post-graduate education and learning experiences for the 2024-2025 term.
- D. Department update
1. No updates.

XIII. **Adjournment:** Meeting was adjourned at 10:04 a.m.

- A. Motion to adjourn the meeting made by Dr. Nikocecic and seconded by Dr. Schriever. The motion was passed.
- B. Next meeting is scheduled for April 24, 2025, 8:30 a.m. – 10:30 a.m.

Approved by the DUR Advisory Board on April 24, 2025.